PFF preparation tail (storage / sonication / pilot validation), Vargas 2019 Summary of a-syn animal models Table 1, Transgenic vs Vector vs Injection matrix, MOA of aSyn spreading axon transport table, Antibodies to aSyn start
PFF preparation (continued)
PFF storage / generation:
37°C with shaking for 7 days, and subjected to a quality test. α-Syn PFFs should not be stored at 4°C or -20°C because dissociation might occur. They should only be stored at -80°C.33 It is advisable to use freshly prepared PFFs. Samples stored in the shortterm at room temperature or at -80°C for up to 1.5 years retain pathogenicity but can lose activity.34 To generate pathogenic species of PFFs, the fibrils should be diluted and sonicated immediately before use. To achieve consistent pathogenicity, sonication must produce short fibrils with a length of 50 nm or shorter as the pathogenicity of α-syn PFFs depends on the structure and size of the fibrils.35,36 Other than regular quality control experiments used to validate the conversion of monomeric α-syn to PFFs, in vivo pilot studies are required to validate the pathogenicity of PFF species before any long-term in vivo studies. All parameters at every step in the standard protocol should be validated and tailored to each study’s purposes and models.34
Summary of a-syn animal models (J.Y. Vargas et al., Ageing Research Reviews 50 (2019) 89-101)
Table 1 — Summary of in vivo studies representing the major milestones in the understanding of α-syn prion-like spreading properties.
| Experimental approach | Animals | Material assayed | Region of interest | Time points | References |
|---|---|---|---|---|---|
| Engrafted neurons on PD brains | Thy-1 α-syn transgenic mice | Mouse cortical neuronal stem cells | Hippocampus | 4 weeks | Desplats et al., 2009 |
| Rats (WT) injected with AAV-α-syn | Rat embryonic ventral mesencephalic neurons | Striatum | 1 week 2 weeks 4 weeks | Angot et al., 2012 | |
| Intracerebral inoculation/expression of α-syn | C57BL6/C3H mice (WT) | Mouse α-syn fibrils | Striatum | 30 days 90 days 180 days | Luk et al., 2012a |
| C57BL/6J mice (WT) | Human α-syn monomers and fibrils | Olfactory bulb | 1 week, 3 h, 12 h, 72 h | Rey et al., 2013 | |
| WT and α-syn null mice, monkeys | α-Syn extracts from the PD patients | Substantia nigra and striatum | 4 weeks 16 weeks 56-68 weeks | Recasens et al., 2014 | |
| Rats (WT) | Human α-syn oligomers, fibrils and ribbons. AAV-α-syn | Substantia nigra | 7 days 120 days | Peelaerts et al., 2015 | |
| Peripheric administration of α-syn | WT and α-syn null mice | AAV-GFP AAV-α-syn | Vagus nerve | 2 weeks 6 weeks 12 weeks | Helwig et al., 2016 |
| WT and α-syn transgenic mice | α-Syn fibrils | Sciatic nerve | 14 weeks | Ayers et al., 2014b | |
| WT and α-syn transgenic mice | Gut microbiota from PD donors | 12-13 weeks and 24-25 weeks | Sampson et al., 2016 |
Transgenic vs Vector-mediated α-syn vs Injection comparison
| NHP available? | a-syn expression level | a-syn accumulation/aggregation | a-syn propagation | Neurodegeneration | Behavior | |
|---|---|---|---|---|---|---|
| Transgenic | X | Too much than human | o | X | X (alpha-synuclein cell loss has been reported in only 2 of the many mouse models over-expressing alpha-syn: a line expressing a doubly mutated protein, which is not found in patients, and in a line expressing a truncated alpha-syn [36, 37]; ↓ 50% reduction in TH-positive neurons, 24-weeks post-AAV injection) | X |
| Vector-mediated α-syn (vector-mediated α-syn overexpression) | O | Too much than human | O (inclusions develop) | X | ||
| Injection | o | Less than AAV | o | o | o |
MOA of aSyn spreading
Retrograde axonal spread (transport) 보인다는 것 같음 (동물모델에서 sciatic nerve 까지 가는 듯).
| de axons (showing direction) | Secreted into extracellular space | In ECF | Uptake | Recipient cell | Pathological aggregation | Lewy bodies | Total a-syn | Secondary secretion |
|---|---|---|---|---|---|---|---|---|
| retrograde AT (Brundt 2012) | Exosome | passive way (diffusion) | 건강함 (Both fibrillar form of αSyn and non-fibrillar oligomeric αSyn and aggregated αSyn (in lysosome with a half life of 7 h in SH-SY5Y cells & RAT embryonic cortical neuron) [10] (Lee 2008 #620), monomeric αSyn 도 있지만 endogenous monomers αSyn 일컬 (Bae 2014 #610)) | Co-aggregation with resident αSyn, can recruit other soluble monomers that assemble to form aggregates9 | fiber but not like LB rounded | |||
| antero & retro AT (Brahic 2016) | exophagy | active way (endocytosis) | α-syn associates to lipid rafts, and more specifically to the glycolipid ganglioside GM1, which is abundantly expressed in the brain (Fortin et al., 2004; Olive et al., 1995). | |||||
| (Bae, 2014 #610) Aggregated aSyn 만 exocytosis 된다 b/c 이런 놈만 세포막에 구멍냄 ((Vasili, 2019 #616). | extracellular proteases, such as MMP3, directly cleaves secreted a-syn monomers | |||||||
| Extracellular aSyn Activates microglia → kills DA neurons (Lee, 2008 #620) |
Antibodies to aSyn (start)
| Pathologic conversion | Pathological aggregation | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| monomeric | tetramer | Phosphorylated a-syn | Misfolded monomer | B-pleated sheet | Insoluble | Oligomeric (still soluble) | protofibril | insoluble amyloid-like fibril | Lewy bodies | Total a-syn | |
| (antibody) | (20200414) ADx Neurosciences, TV Q3 FY2020, CS : Q42020, • 기존 : anti-pS129 a-syn antibody | (Waxman, 2008 #535) Syn505, Syn506 and Syn514 recognize conformational variants of α-syn | Thioflavin-staining (antibody는 아니지만) | (20200414) ADx Neurosciences, TV Q4 FY2020, CS : Q3 FY2021, | mouse anti-a-syn fibrils [02; [43]] | ||||||